Summary

  • OMB Director Russ Vought’s proposed 411-page rule would consolidate authority over approximately $1.5 trillion in federal discretionary grants under political appointees, requiring awards to “demonstrably advance the president’s policy priorities” and barring funding for projects that “promote(s) anti-American values.”
  • Stand Up for Science’s analysis of roughly 10,000 NIH-funded clinical trials estimates nearly half could be discontinued under the rule’s criteria, including more than 1,000 cancer-related studies and hundreds of pediatric, suicide, heart disease, and diabetes trials.
  • Former NIH program official Elizabeth Ginexi, who resigned after 22 years, has characterized the rule as part of a broader degradation of career-staff capacity at research agencies following Department of Government Efficiency staffing reductions.
  • The advocacy response—a three-pillar strategy of public comment, legal action, and congressional lobbying—faces structural constraints including vague enforcement standards, slow-moving litigation timelines, and a significant knowledge gap among lawmakers about the rule’s contents.

The rule and its scope

The Office of Management and Budget, under Director Russ Vought, published a proposed 411-page rule on May 29, 2026, that would place all federal discretionary grants—including scientific research, veterans housing, and small business funding—under the authority of political appointees. The rule requires that awards “demonstrably advance the president’s policy priorities” and bars funding for projects that “promote(s) anti-American values,” according to text quoted by former NIH program official Elizabeth Ginexi on her Substack. Stand Up for Science founder Colette Delawalla, a clinical psychologist and Emory University researcher, has estimated the affected spending apparatus at roughly $1.5 trillion, describing the proposal as a “$1.5tn slush fund.”

The administration’s stated justification appears in fact sheets titled “Ending Weaponization of the Federal Government” and “Cuts to Woke Programs,” which assert that the existing grant system has been captured by ideological agendas and requires political oversight to ensure taxpayer dollars serve national interests. The stated procedural interest is executive authority over discretionary spending—a position at least one unnamed House Democrat endorsed, telling Delawalla that “the executive branch should have the right to cancel grants.” The substantive interest, signaled by the rule’s language requiring alignment with “the president’s policy priorities,” extends to directional control over the research agenda itself. An unstated interest, common to administrations seeking to consolidate institutional authority, may be the reshaping of the federal workforce’s relationship to political leadership.

Who is affected and what interests are at stake

Stand Up for Science and its founder, Delawalla (recognized by Scientific American as one of five young scientists “making waves”), have articulated a security interest in preserving research infrastructure. The organization’s analysis of approximately 10,000 NIH-funded clinical trials found that nearly half could be discontinued for reasons ranging from use of prohibited words such as “equity” to the inclusion of international collaborations. Among the discontinued trials, the organization estimates, would be more than 1,000 cancer-related studies and hundreds each focused on pediatric, veteran, suicide, heart disease, and diabetes populations. Delawalla described the fight as “fundamentally about democracy,” stating: “If you tell people in a country they’re not allowed to study certain things with federal money, you’re not in a free country.” A relational-institutional interest is visible in the organization’s effort to mobilize non-scientists, whom Delawalla characterized as “easier to mobilize” because “they’ve never been told they need to remain apolitical.”

Elizabeth Ginexi, who resigned from the NIH after 22 years, represents former and current federal scientists whose interests include professional autonomy, institutional continuity, and merit-based grant-making. She characterized the rule as “a multi-front assault unprecedented in my lifetime” and stated that Department of Government Efficiency staffing cuts had made it impossible for her to do her job. Her decision to resign signals that her alternative to operating within the system was to exit it.

Patients and research subjects enrolled in the approximately 10,000 clinical trials Stand Up for Science analyzed have interests in continued access to experimental treatments and in the continuation of safety monitoring. These interests are largely unrepresented in the negotiating structure. Delawalla cited a clinical trial designed to help parents who become suicidal after the death of an infant as an example of a study that would likely be discontinued because it involves international collaboration the rule prohibits.

Cascading consequences

The rule arrives at agencies already degraded by staffing reductions from the Department of Government Efficiency. Fewer career officials would be positioned to interpret vague standards or challenge overreach, amplifying the risk of arbitrary enforcement. The proposed rule does not create an independent appeals process or review board for grant decisions, concentrating authority in political appointees without the institutional checks that career officials previously exercised.

A prospective-hindsight analysis identifies a plausible failure pathway: political appointees gain authority to approve or cancel individual grants based on the vague standard of “anti-American values,” producing a wave of uncertainty among program officers and researchers. Agencies begin pausing or terminating studies touching on topics the administration deems sensitive—health disparities, gender, suicide prevention, international collaborations. The absence of a clear definition of “anti-American values” leads to arbitrary enforcement. The prohibition on international work causes U.S. researchers to be removed from multi-site trials, ceding leadership to other nations. Analogous restrictions on federal funding for stem cell research under past administrations, while narrower in scope, demonstrated how political directives can abruptly halt lines of inquiry and push researchers into alternative funding sources or abroad.

Legal challenges would likely be slow-moving, and courts may decline to grant emergency relief. Preliminary injunctions are available but require a showing of irreparable harm—the standard established in Winter v. Natural Resources Defense Council, 555 U.S. 7 (2008). Courts have historically deferred to executive authority over discretionary spending to a degree that may delay injunctive relief. The number of grants flagged or cancelled in the first quarter after the rule takes effect, particularly those with keywords like “equity” or with international partners, serves as a leading indicator. If cancellations exceed 500 within the first three months, that would signal a rapid chilling effect and could trigger congressional oversight hearings or emergency legal motions.

The advocacy response and its structural risks

Stand Up for Science is pursuing a three-pillar strategy: public comment, legal action, and congressional lobbying. The public comment process had drawn nearly 31,000 submissions as of Thursday morning, with a July 13 deadline. The legal strategy includes a virtual meeting Delawalla held last Friday with approximately 50 attorneys from across the country to discuss possible litigation if the rule is finalized.

A prospective-failure analysis of this strategy identifies four risk classes. First, assumption failure: the public comment process may lack dispositive force. The Administrative Procedure Act requires agencies to consider public comments, but the standard of review is “reasoned decisionmaking” (Motor Vehicle Manufacturers Assn. v. State Farm, 463 U.S. 29 (1983)), not whether comments outnumber support. Stand Up for Science’s documentation of specific trials and affected patient populations appears designed to generate the kind of specific, citable harm that courts weigh, suggesting awareness of this constraint. Second, context-shift failure: the rule may be finalized before litigation reaches a merits decision. Third, interaction failure: Delawalla’s characterization of the rule’s purpose as “fascism” may mobilize the organization’s base while narrowing the coalition reachable through congressional engagement. The unnamed House Democrat’s dismissal—Delawalla recounted him telling her “you’re just protesters”—may reflect a broader pattern in which the advocacy frame alienates moderate lawmakers whose procedural influence would be needed to constrain the rule through legislation. Fourth, motivational failure: the disparity between the rule’s scope and the organization’s capacity—founded last year—creates a sustainability risk. Sustained engagement from scientists who “typically avoid political engagement,” as Ginexi characterized them, is necessary but uncertain.

Institutional channels and framing

Delawalla’s Capitol Hill meetings with more than 30 members of Congress revealed what she described as a “wide knowledge gap.” Only Senator Chris Van Hollen, a Maryland Democrat, was reportedly familiar with the full 411-page rule. The public comment process, which under the APA requires agencies to consider submissions but does not require them to adopt them, leaves the executive branch with final authority to issue the rule without legislative consent.

The emergence of Stand Up for Science as a public-facing advocacy organization, rather than the traditional model of professional-society engagement, signals a shift in how the scientific community is organizing to defend its institutional interests. Visible signals of escalation include the hardening of rhetoric on both sides, the recruitment of legal capacity, and the breakdown of prior channels of professional communication between NIH staff and political leadership.

Under the Ury conflict-resolution framework, the roles available to the surrounding community are constrained. Stand Up for Science and approximately 50 attorneys preparing litigation occupy an equalizer role, though the power asymmetry between a rule-making federal agency and a year-old advocacy organization remains significant. Media outlets including the Guardian, which first reported the rule’s details, serve a witness function. Congressional committees could serve a mediator role, but the knowledge gap identified in Delawalla’s meetings constrains Congress’s capacity to surface the procedural and substantive interests that remain unarticulated on both sides. No bridge-builder role is currently occupied; the 411-page rule was proposed without a collaborative process that might have surfaced shared interests in research quality and accountability. The administration’s interest in directional control and the research community’s security interest are not being directly compared under any structured encounter. If the administration is not open to accommodation, a mediation process could allow the rule to be finalized without altering the underlying power imbalance—a dynamic that conflict-resolution scholar William Ury identifies as a risk when a stronger party sees no need to concede.

When one party is exercising formal rulemaking authority and the other is challenging that authority’s scope, the roles available to the surrounding community are limited to comment periods and litigation—institutional channels whose effectiveness depends on legal standards and judicial willingness to review executive action. The convergence of vague enforcement criteria and centralized authority in political appointees creates a structural risk that funding decisions will be driven by political alignment rather than scientific merit. Whether the public comment, legal, and congressional responses can alter the rule’s trajectory remains an open question.

Analytical techniques used in this piece

This analysis applies the methods below. Each links to a short, plain-English explainer you can read and reuse.

Interest Mapping
Separates parties’ stated positions from their underlying interests (Fisher & Ury).
Pre-Mortem (Action Plan)
Imagines the plan has already failed, then works backward to find out why.
The Third Side
Takes the vantage of the surrounding community that has a stake in resolving a conflict (Ury).
Bayesian Reasoning
Starting from base rates and updating beliefs proportionally as evidence arrives.
Brinkmanship
Manufacturing shared risk at the edge of catastrophe to force the other side to blink.